Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Nathan Kalil

Podiatrist, Foot & Ankle Surgery Columbus, OH Doctor of Podiatric Medicine

NPI 1437772431 CMS profile 8802283

3255 E Livingston Ave, Columbus, OH 43227

Open in the dashboard

General payments

$10,597

89 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Kalil of Columbus, OH is reported in the CMS Open Payments database as having received $10,597 across 89 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $317 7
2024 General $2,206 18
2023 General $4,573 39
2022 General $3,470 23
2021 General $16 1
2020 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Kalil
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Nathan Kalil were reported at $317. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Nathan Kalil Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $14 $191 $62–$691 $114
2021 $16 $329 $104–$1,341 $132
2022 $3,470 $419 $125–$1,611 $149
2023 $4,573 $377 $128–$1,164 $160
2024 $2,206 $394 $134–$1,168 $164
2025 $317 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Orthofix Medical, Inc. $3,545 33 payments
  2. Vilex in Tennessee, Inc. $1,642 9 payments
  3. Medline Industries, Inc. $1,209 9 payments
  4. Rock Medical Orthopedics, Inc. $1,200 1 payment
  5. restor3d, inc. $779 5 payments
  6. Davol Inc. $425 3 payments
  7. Medical Device Business Services, Inc. $339 2 payments
  8. Integra LifeSciences Corporation $274 3 payments
  9. Horizon Therapeutics plc $250 2 payments
  10. Biocomposites Inc $148 1 payment
  11. Other $786 21 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $5,601 34 payments
  2. Food and Beverage $3,457 52 payments
  3. Education $1,539 3 payments
Products named General payments · program years 2020–2025
  1. TrueLok $5,437 48 payments
  2. ALPHALOK $1,642 9 payments
  3. MEDLINE UNITE $350 4 payments
  4. ARISTA AH FLEXITIP BD Interventional Surgery $279 2 payments
  5. Integra $274 3 payments
  6. KRYSTEXXA $250 2 payments
  7. Stimulan $148 1 payment
  8. ARISTA AH FlexiTip Surgery $146 1 payment
  9. Kerecis Omega3 SurgiClose $138 2 payments
  10. Kerecis Omega3 GraftGuide $138 2 payments
  11. Other $1,090 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

103

Median for Podiatry: 160

Drug cost

$810

Median for Podiatry: $2,368

Branded share of claims

68.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 23 $269
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 24 $150
Cefadroxil Generic 18 $150
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $113
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $100
Meloxicam Generic 14 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$25,805

Medicare's payments for the services billed

Medicare patients

228

Average age 78

Services billed

469

106 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Arthritis 54%
Chronic kidney disease 47%
Ischemic heart disease 33%
Heart failure 25%
Atrial fibrillation 25%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record